Calcium antagonist in the treatment of symptomatic dermographism

Low-dose and high-dose studies with nifedipine

F Lawlor, Anthony Ormerod, M W Greaves

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The effect of nifedipine on subjective symptoms and objective dermographometer induced whealing was assessed independently in two double-blind cross-over trials in which active drug or placebo were taken for 2 weeks. The lower dose study used nifedipine 5 mg 3 times daily and gave rise to symptomatic improvement as assessed by diary card and visual analogue scale in 5 of 11 patients. This was not statistically significant and was not accompanied by a reduction in dermographometer-induced wheal and flare responses except at highest pressures. In a separate study 7 patients were treated with nifedipine 10 mg 3 times daily. No change in whealing occurred, 3 patients' symptoms became worse and only 1 showed symptomatic improvement on nifedipine. Side effects were frequent at this dose. The reasons for the unfavourable response despite in vitro evidence for inhibition of mast cell degranulation by this drug are discussed.
Original languageEnglish
Pages (from-to)287-291
Number of pages5
JournalDermatologica
Volume177
Issue number5
DOIs
Publication statusPublished - 1 Jan 1988

Fingerprint

Nifedipine
Calcium
Cell Degranulation
Therapeutics
Visual Analog Scale
Mast Cells
Pharmaceutical Preparations
Cross-Over Studies
Placebos
Pressure

Keywords

  • Adolescent
  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nifedipine
  • Random Allocation
  • Urticaria
  • Symptomatic dermographism
  • Unfavourable therapeutic response

Cite this

Calcium antagonist in the treatment of symptomatic dermographism : Low-dose and high-dose studies with nifedipine. / Lawlor, F; Ormerod, Anthony; Greaves, M W.

In: Dermatologica, Vol. 177, No. 5, 01.01.1988, p. 287-291.

Research output: Contribution to journalArticle

Lawlor, F ; Ormerod, Anthony ; Greaves, M W. / Calcium antagonist in the treatment of symptomatic dermographism : Low-dose and high-dose studies with nifedipine. In: Dermatologica. 1988 ; Vol. 177, No. 5. pp. 287-291.
@article{fa02e2113f344a6383751df569c1dff4,
title = "Calcium antagonist in the treatment of symptomatic dermographism: Low-dose and high-dose studies with nifedipine",
abstract = "The effect of nifedipine on subjective symptoms and objective dermographometer induced whealing was assessed independently in two double-blind cross-over trials in which active drug or placebo were taken for 2 weeks. The lower dose study used nifedipine 5 mg 3 times daily and gave rise to symptomatic improvement as assessed by diary card and visual analogue scale in 5 of 11 patients. This was not statistically significant and was not accompanied by a reduction in dermographometer-induced wheal and flare responses except at highest pressures. In a separate study 7 patients were treated with nifedipine 10 mg 3 times daily. No change in whealing occurred, 3 patients' symptoms became worse and only 1 showed symptomatic improvement on nifedipine. Side effects were frequent at this dose. The reasons for the unfavourable response despite in vitro evidence for inhibition of mast cell degranulation by this drug are discussed.",
keywords = "Adolescent, Adult, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Male, Middle Aged, Nifedipine, Random Allocation, Urticaria, Symptomatic dermographism, Unfavourable therapeutic response",
author = "F Lawlor and Anthony Ormerod and Greaves, {M W}",
year = "1988",
month = "1",
day = "1",
doi = "10.1159/000248580",
language = "English",
volume = "177",
pages = "287--291",
journal = "Dermatologica",
issn = "0011-9075",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Calcium antagonist in the treatment of symptomatic dermographism

T2 - Low-dose and high-dose studies with nifedipine

AU - Lawlor, F

AU - Ormerod, Anthony

AU - Greaves, M W

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The effect of nifedipine on subjective symptoms and objective dermographometer induced whealing was assessed independently in two double-blind cross-over trials in which active drug or placebo were taken for 2 weeks. The lower dose study used nifedipine 5 mg 3 times daily and gave rise to symptomatic improvement as assessed by diary card and visual analogue scale in 5 of 11 patients. This was not statistically significant and was not accompanied by a reduction in dermographometer-induced wheal and flare responses except at highest pressures. In a separate study 7 patients were treated with nifedipine 10 mg 3 times daily. No change in whealing occurred, 3 patients' symptoms became worse and only 1 showed symptomatic improvement on nifedipine. Side effects were frequent at this dose. The reasons for the unfavourable response despite in vitro evidence for inhibition of mast cell degranulation by this drug are discussed.

AB - The effect of nifedipine on subjective symptoms and objective dermographometer induced whealing was assessed independently in two double-blind cross-over trials in which active drug or placebo were taken for 2 weeks. The lower dose study used nifedipine 5 mg 3 times daily and gave rise to symptomatic improvement as assessed by diary card and visual analogue scale in 5 of 11 patients. This was not statistically significant and was not accompanied by a reduction in dermographometer-induced wheal and flare responses except at highest pressures. In a separate study 7 patients were treated with nifedipine 10 mg 3 times daily. No change in whealing occurred, 3 patients' symptoms became worse and only 1 showed symptomatic improvement on nifedipine. Side effects were frequent at this dose. The reasons for the unfavourable response despite in vitro evidence for inhibition of mast cell degranulation by this drug are discussed.

KW - Adolescent

KW - Adult

KW - Clinical Trials as Topic

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Nifedipine

KW - Random Allocation

KW - Urticaria

KW - Symptomatic dermographism

KW - Unfavourable therapeutic response

U2 - 10.1159/000248580

DO - 10.1159/000248580

M3 - Article

VL - 177

SP - 287

EP - 291

JO - Dermatologica

JF - Dermatologica

SN - 0011-9075

IS - 5

ER -